tailieunhanh - Pioglitazone use and risk of bladder cancer: An in vitro study

Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years. The aim of this study was to investigate the in vitro effects of PIO on normal urothelial transitional epithelium (NUTE) cells and bladder cancer (J82) cells to further evaluate the risk. | Pioglitazone use and risk of bladder cancer: An in vitro study

TÀI LIỆU MỚI ĐĂNG
5    165    1    02-12-2024
64    126    0    02-12-2024